

FOR IMMEDIATE RELEASE

Mike Mejer

Mike@GreenLaneCommunication.com

631-671-4778



Spectral Analytics Releases Independent Scientific Data Comparing Their CBD Transdermal Patch To Other Leading CBD Transdermal Patches

Manhattan, N.Y. (December 17, 2020) Spectral Analytics, a nutraceutical research company, conducted an independent study with [Teledyne Hanson Research](#) which showed that Spectral Analytics' transdermal patch containing CBD outperformed transdermal patches from other brands, and proved to be highly effective for a 24-hour time period with a consistent, steady release of cannabinoids.

Therefore, Spectral Analytics released a scientific white paper which demonstrates that their proprietary Transdermal Patch containing cannabidiol (CBD) and other ingredients is effective for a 24-hour duration compared to CBD transdermal patches of other brands. The diffusion rates of the other leading brands in the cannabinoid industry did not all show a 24-hour efficacy.

"I am very pleased with the results that we received by an independent lab who performed an efficacy study. The results clearly demonstrate that the CBD Transdermal Patches from Spectral Analytics' Aevum Therapy brand are effective from application to removal for a period of 24-hours," stated Christina DiArcangelo, Chief Clinical R&D Officer, Spectral Analytics and CEO, Founder, [Affinity Bio Partners](#).

An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc., is that the patch provides a controlled release of the medication into the patient.

"As stated in the paper that I authored with Dr. Bryan Doner and David A. Dawson, transdermal drug delivery has made an essential contribution to medical practice, and transdermal patches including cannabidiol should be considered a fourth-generation delivery system for patients. When patients are purchasing their patches, it is essential for them to know how long the patch will actually provide them with relief. Patients are paying for the transdermal patches out of pocket and deserve to know if the patch will work for a 24-hour period if that is what is being stated by the company, and if they'll receive their monetary value from the initial purchase of the patch. It is shameful that other companies are misleading patients," added Christina DiArcangelo.

For more information about the study and to access the full white paper, please [click here](#).

###

FOR IMMEDIATE RELEASE

Mike Mejer

Mike@GreenLaneCommunication.com

631-671-4778



About Spectral Analytics

Spectral Analytics Inc. is a nutraceutical research company with the fundamental premise that phytocannabinoid supplementation of the endocannabinoid system through the use of cannabinoids and other nutraceuticals will improve health.

About AEVUM Therapy

AEVUM Therapy's mission is to meet patients where they're at and to help them get to where they want and need to be with their health and wellness. AEVUM is known as the Gold Standard in wellness for a patient's face and body, with products that consist of gold nanoparticles (NGP's) designed as nanocarriers - functionalized with each of the 20 collagen peptides that are native to the human body.

About Affinity Bio Partners, Christina DiArcangelo, CEO

Christina DiArcangelo, CEO and Founder of Affinity Bio Partners, CEO, Board President of Affinity Patient Advocacy, CEO, the Christina DiArcangelo brand. CEO and Co-Founder of AI Health Outcomes, CannaBot™ and DRBot™, has forged a world-class reputation in the biotechnology and pharmaceutical industry over the past 22 years. Her engagements have led to numerous industry awards, keynote speaking engagements, multitude of global clinical trials as well as working on several drugs that have received FDA approval. Throughout the course of Christina's career, she has acted in various capacities for Global Clinical Research Organizations, Pharmaceutical Companies and Biotechnology Companies.

FOR IMMEDIATE RELEASE

Mike Mejer

Mike@GreenLaneCommunication.com

631-671-4778

